China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
This article was originally published in PharmAsia News
Executive Summary
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.
You may also be interested in...
China’s New Good Supply Practices Regs Require Electronic Barcodes; Raise Bar To Entry
The Ministry of Health’s GSP regulation tries to plug a hole in supply chain security through tighter IT controls, such as requiring electronic barcodes.
Pfizer Global Security Regional Director Harry Waskiewicz On Busting Counterfeit Drugs: An Interview With PharmAsia News (Part 2 of 2)
Pfizer case studies show counterfeiting now goes far beyond a Viagra problem.
Pfizer Global Security Regional Director Harry Waskiewicz On Busting Counterfeit Drugs: An Interview With PharmAsia News (Part 1 of 2)
Pfizer case studies show counterfeiting now goes far beyond a Viagra problem.